• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Angioplasty and Stenting.
Authors: Leung TW, Wabnitz AM, Miao Z, Chimowitz MI Abstract The high rate of recurrent strokes in patients with intracranial atherosclerotic disease (ICAS) despite medical therapy prompted intracranial angioplasty and/or stenting an adjunctive treatment option. The minute calibers of cerebral arteries, the relative paucity of supporting medial and adventitia layers, the presence of end-anastomosing perforator branches, and the vascular tortuosity from groin to head all demand specialized operative skills and dedicated tools. Since the stroke mechanism of ICAS is diverse, patient selection for endovascular treatmen...
Source: Frontiers of Neurology and Neuroscience - December 15, 2016 Category: Neuroscience Tags: Front Neurol Neurosci Source Type: research

Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
Antiplatelet therapy is the cornerstone of secondary prevention against acute thrombotic events in patients with cardiovascular disease [1]. Health Organizations around the world recommend combination therapy with aspirin and a P2Y12 receptor inhibitor for up to one year following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and lifelong aspirin therapy thereafter [2]. Vorapaxar, a first-in-class novel protease-activated receptor (PAR)-1 antagonist, was approved in addition to standard antiplatelet therapy, to further reduce the risk of myocardial infarction (MI), stroke, cardiovascular dea...
Source: Thrombosis Research - October 30, 2015 Category: Hematology Authors: Marie Lordkipanidzé Source Type: research

FDA Approves Expanded Indication for AstraZeneca Medications to Include Long-Term Use in Patients with a History of Heart Attack
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. With this expanded indication, BRILINTA is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI, also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.
Source: News from Angioplasty.Org - September 3, 2015 Category: Cardiology Source Type: news

FDA clears system to reduce stroke risk during stent and angioplasty procedures
The U.S. Food and Drug Administration today cleared for marketing the ENROUTE Transcarotid Neuroprotection System (ENROUTE TNS), for use during a minimally invasive procedure to restore normal blood flow to narrowed carotid arteries. It is the first device designed to access the carotid arteries through an incision in the neck, instead of the groin, and uses a blood flow reversal system to capture pieces of the blockage dislodged during the procedure.
Source: Food and Drug Administration - February 9, 2015 Category: American Health Source Type: news